Batoclimab

2024 saw advancements in myasthenia gravis (MG) treatment, including batoclimab's success in trials, new MG triggers like hair dye chemicals, and statins' rare worsening of symptoms. FDA approved new MG drugs, and research linked autoimmune thyroid disease with higher MG risk.

The Myasthenia Gravis Treatment Market is set to grow significantly by 2034, driven by improved diagnostics, emerging therapies, and increased awareness. Key companies like Horizon Therapeutics and Amgen are developing novel treatments. The market size reached USD 4,950 million in 2023, with the U.S. seeing 129 thousand cases.

The FcRn inhibitor market report by ResearchAndMarkets.com provides insights into historical and competitive landscapes, market trends, emerging drugs, and forecasts from 2020 to 2034. Key players like Johnson & Johnson, UCB Biopharma, Pfizer, and Immunovant are developing FcRn inhibitors for autoimmune diseases. Prominent drugs include VYVGART, RYSTIGGO, and batoclimab, with positive trial results and FDA approvals. The market is expected to grow due to increasing diagnoses and emerging therapies.

The 'Graves' Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current pipeline landscape for Graves' Disease treatments, including detailed descriptions of drugs like Batoclimab, VRDN-001, and Linsitinib, which are in various stages of clinical development. The report highlights key companies such as Viridian Therapeutics, Immunovant Sciences, and Sling Therapeutics, and covers therapeutic assessments, pipeline development activities, and emerging trends in drug development for Graves' Disease.

Immunovant reports five IND applications cleared for IMVT-1402 across various therapeutic areas, with potential registrational trials in Graves’ disease and rheumatoid arthritis expected by 2025. Batoclimab trials in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy are fully enrolled, with data expected by March 2025. Immunovant appoints Melanie Gloria as COO and announces financial results for Q2 2024.

HanAll Biopharma reported Q3 2024 revenue of 36.8 billion KRW, an 11.7% increase from 2023, with an operating profit of 430 million KRW. Key updates include progress in autoimmune disease treatments, Phase 1 results for HL192 expected in November 2024, and discontinuation of certain oncology programs. The company focuses on R&D and strategic growth to enhance its global presence.

Immunovant to launch late-stage trial for Graves' disease, targeting FcRn to block harmful IgG autoantibodies, aiming to improve control of hyperthyroidism and thyroid eye disease.

Immunovant reports positive batoclimab trial results in Graves’ disease, with 76% response rate. IMVT-1402, another candidate, moves closer to pivotal trial. Batoclimab shows 56% ATD-Free Response and is also being evaluated for thyroid eye disease and CIDP.